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Abstract
Background: To survey cancer patients who consume an extract of the Basidiomycetes Agaricus
blazei Murill mushroom (Sen-Sei-Ro) to measure their self-assessment of its effects and to develop
an instrument for use in future randomized trials.
Methods: We designed, translated and mailed a survey to 2,346 Japanese consumers of Sen-Sei-
Ro self-designated as cancer patients. The survey assessed consumer demographics, cancer history,
Sen-Sei-Ro consumption, and its perceived effects. We performed exploratory psychometric
analyses to identify distinct, multi-item scales that could summarize perceptions of effects.
Results:  We received completed questionnaires from 782 (33%) of the sampled Sen-Sei-Ro
consumers with a cancer history. Respondents represented a broad range of cancer patients
familiar with Sen-Sei-Ro. Nearly all had begun consumption after their cancer diagnosis. These
consumers expressed consistently positive views, though not extremely so, with more benefit
reported for more abstract benefits such as emotional and physical well-being than relief of specific
symptoms. We identified two conceptually and empirically distinct and internally consistent
summary scales measuring Sen-Sei-Ro consumers' perceptions of its effects, Relief of Symptoms
and Functional Well-being (Cronbach's alpha: Relief of Symptoms, α = .74; Functional Well-Being,
α = .91).
Conclusion: Respondents to our survey of Sen-Sei-Ro consumers with cancer reported favorable
perceived effects from its use. Our instrument, when further validated, may be a useful outcome
in trials assessing this and other complementary and alternative medicine (CAM) substances in
cancer patients.
Background
Complementary and alternative medicine (CAM) is
widely used by patients who are undergoing or have com-
pleted medical treatment for cancer [1,2]. While conven-
tional therapies, including surgery, radiation therapies
and anticancer drugs, are targeted at tumors, their side
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effects on normal organs may significantly compromise
quality of life during and after treatment. For many
patients, CAM approaches may be pursued in order to
augment conventional modalities' anti-cancer effects, as
well as to reduce treatment-related symptoms and other
side effects that diminish their quality of life [3-5]. While
the distinction between biological end points and the
broader perspective of outcomes research is important to
any assessment of oncology practice [6], it is particularly
important when patients use CAM therapy for these less
clearly defined objectives. However, few investigations
have attempted to measure rigorously the goals patients
have in using these substances and whether they achieve
them. We have learned that measuring quality of life out-
comes in cancer patients in ways that accurately reflect
their perspectives is challenging [7-9]. We found an
opportunity to address this challenge when asked to
design a survey of Japanese users of a widely used CAM
substance, Sen-Sei-Ro.
Sen-Sei-Ro is an extract derived from mushroom, Basidio-
mycetes Agaricus blazei Murill, that has been reported to
have a stable antioxidant activity [10], as well as antimuta-
genic [11,12], antitumorigenic [13-16], chemopreventive
[17] and immunostimulatory effects [17,18], and
improved quality of life associated with immunological
effects in a cohort of cancer patients [19]. In addition, a
study of the 12,465 residents of Nagano Prefecture of
Japan found lower cancer death rates among mushroom
farmers compared to other residents of the prefecture
[17]. Sen-Sei-Ro has been manufactured and marketed in
Japan by Kyowa-S.S.I. since 1991 and, according to com-
p a n y  e s t i m a t e s ,  h a s  b e e n  p u r c h a s e d  b y  a s  m a n y  a s
700,000 cancer patients. In previous surveys of its con-
sumers the company has found that improved quality of
life was an important rationale for Sen-Sei-Ro consump-
tion. We constructed a survey of Sen-Sei-Ro consumers
with cancer to identify patients' demographic and medical
characteristics, patterns of use, perceived benefits and
rationale for use of this product. We also hoped to identify
domains of interest for a patient-reported measure to be
used in a controlled clinical trial of its effects on quality of
life of cancer patients. Such an instrument, once validated,
could also be applied more broadly to measuring the
impact of other CAM products taken by cancer patients for
purposes other than specific anti-tumor effects.
Methods
A total of 2,346 Japanese consumers of Sen-Sei-Ro, listed
in the Kyowa-S.S.I. database, were mailed a brief ques-
tionnaire in July 2001. Using a common industry practice
of including questionnaires as product package inserts,
the company had surveyed the consumption habits and
health status of Sen-Sei-Ro consumers in 2000. Consum-
ers who indicated they had cancer were eligible for the
present survey. We developed a draft survey instrument in
English, which was translated into Japanese and then
back-translated into English to confirm the preservation
of item definitions. A subsequent round of revisions was
made. The instrument was mailed to current customers
who in the previous survey had indicated that they either
had been treated for cancer or used the product to mitigate
the effects of cancer or cancer treatment.
The questionnaire included 37 items that assessed demo-
graphics (i.e., gender, age, and marital status), cancer his-
tory, consumption of Sen-Sei-Ro, and its perceived effects.
Cancer status included questions about the primary
tumor (i.e., 'Where did your cancer start?") and current
treatment with intravenous chemotherapy, oral chemo-
therapy or radiation. It assessed consumption by asking
when its use began relative to the cancer diagnosis and
treatment and the amount and duration of use. Seven
questions asked about the extent to which drinking Sen-
Sei-Ro helps to: strengthen one's body so it can fight can-
cer and resist other illnesses, reduce symptoms of cancer
and the side effects of treatment, cure cancer, feel better
emotionally, and engage cancer spiritually. Finally, two
items assessed motives for use: the importance of one's
own efforts in fighting cancer, relative to "what doctors
do," and family support for the notion that drinking it
"will help me fight cancer."
Respondents' perceptions of more specific effects on qual-
ity of life were assessed by asking about 17 changes they
may have noticed "about your body, how you feel physi-
cally, and how you feel emotionally" since they had been
taking Sen-Sei-Ro. Response options included "better,"
"worse," and "about the same." These items were based
on the previous survey, the clinical experiences of physi-
cians in Korea who used it as part of their cancer patients'
care [19], and our previous experience in assessing quality
of life in cancer patients. The items were designed to assess
a broad array of treatment side effects and aspects of phys-
ical function and emotional well being.
The analysis was designed to describe consumers' percep-
tions of the quality of life effects of using Sen-Sei-Ro and
explore variation in their perceptions with respect to
demographic and medical characteristics and product
usage. In order to examine patterns in perceptions of the
effects we conducted a principal components factor anal-
ysis with orthogonal rotation with the 17 individual
effects items. Each item was coded so that increasing val-
ues indicated greater relief from symptoms. The factor
results were then used to explore the definition of distinct,
multi-item scales that could summarize perceptions of
effects. Following psychometric convention, the Likert
response set was considered and analyzed as an interval
scale [20,21]. Such scales would offer increased overallBMC Complementary and Alternative Medicine 2007, 7:32 http://www.biomedcentral.com/1472-6882/7/32
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reliability compared to reporting multiple individual
items, as well as allow a more parsimonious description
of the effects respondents attribute to using Sen-Sei-Ro.
Associations between scale scores and ordered and nonor-
dered categorical indicators of consumer characteristics
and product usage were evaluated by calculating Spear-
man correlation coefficients, t-tests, and analyses of vari-
ance, as appropriate.
Results
We received completed questionnaires from 782 (33%) of
the sampled Sen-Sei-Ro consumers with a history of can-
cer. The respondents represented a broad range of cancer
patients familiar with both cancer treatment and Sen-Sei-
Ro. Slightly more than half were male (53%), 89% were
married, and the median age was 65, with 87% between
51 and 80 years old (range: 31–91). Most respondents
reported a single cancer, but 19% reported two or more
(Table 1). Lung, colon and gastric cancer patients each
accounted for one-fifth of diagnoses. However, patients
with cancers that only or disproportionately affect women
(uterus, cervix, and breast) outnumbered those with diag-
noses confined to men (prostate), 191 (24%) vs. 75
(10%). Although most of these study participants were
currently receiving cancer therapy, 37% were not, and
23% were receiving oral chemotherapy, radiation or both,
and 39% were receiving intravenous chemotherapy,
which is usually more toxic.
Over 90% of the respondents had used the product for
over 3 months, and over half for more than a year (Table
2). Only 3% of the study participants began using it
before cancer was diagnosed, while approximately one-
third initiated use after diagnosis, another third after treat-
ment began and the remaining patients after treatment
was completed. Nearly all used it daily, and 42% drank
more than one pack each day.
These study participants expressed consistently positive
views, though not extremely so, regarding general bene-
fits. Between 62 and 74% said Sen-Sei-Ro helps in various
respects, such as improving strength to fight cancer and
ameliorating the side effects of treatment (Table 3). How-
ever, only 16% indicated it was a "great help" in building
resistance to illnesses other than cancer, while 31%
strongly endorsed its value in helping spiritually to fight
cancer. The study participants endorsed two indicators of
motivations for using it. Nearly all (93%) agreed, and a
majority (51%) strongly, that relying on doctors alone is
insufficient, implying they may believe that using Sen-Sei-
Ro represents an important additional personal effort.
Nearly all study participants (85%) also agreed that their
families think it helps fight the cancer. Although the fam-
ily's reported endorsement of this belief was somewhat
weaker than the consumer's personal endorsement, virtu-
ally no one rejected it.
Positive and negative effects of Sen-Sei-Ro
The factor analysis of the 17 individual perceived effects
items suggested two distinct constructs: Relief of Symp-
toms and Functional Well-being. The first referred to relief
of specific symptoms and was defined by items pertaining
to likely side effects of cancer and its treatment (e.g., appe-
tite, weight loss, pain, nausea). The second factor was
defined by perceptions of effects on strength, vitality, and
emotional well-being. Subsequent evaluation of scales
defined by these two sets of items, including item-scale
discrimination and internal consistency, identified two
items pertaining to effects on sleep and daytime drowsi-
ness that discriminate poorly. That is, they were equally
correlated with both scales, and thus were deleted. The
remaining items displayed clear discrimination, correlat-
ing highly with their assigned scale and little with the
other. As a result, we defined two conceptually and empir-
ically distinct, and internally consistent (Cronbach's
alpha: Relief of Symptoms, α = .74; Functional Well-
Being, α = .91) summary scales of Sen-Sei-Ro study partic-
ipants' perceptions of its effects relative to their cancer
treatment. We present the useful items remaining after
this analysis in Table 4. Scores were calculated by averag-
ing the scores of the constituent items, and thus ranged
from -1 to +1, with 0 indicating a perceived effect that was
neither positive nor negative.
Scale scores indicate that study participants reported gen-
erally favorable effects as indicated by the positive mean
scores, although the majority of patients reported no
Table 1: Clinical Characteristics of 782 Consumers of Sen-Sei-Ro 
Who Responded to a Survey
Characteristic Number Percent
Number of cancers reported
One 632 80.6
Two 129 16.5
Three or more 21 2.7
Where cancer(s) started
Lung 177 23
Colon 170 22
Stomach 158 20
Liver 127 16
Breast 101 13
Ovaries 40 5
Cervix 29 4
Uterus 21 3
Prostate 75 10
Others (name of the organ or a part of body) 62 8
Current treatment
No active treatment 292 37.4
Receiving oral chemotherapy or radiation only 181 23.2
Receiving intravenous chemotherapy? 307 39.4BMC Complementary and Alternative Medicine 2007, 7:32 http://www.biomedcentral.com/1472-6882/7/32
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effect either way on most individual items, and net scores
of zero were reported by 26% and 37% for Functional
Well-Being and Relief of Symptoms, respectively. The
product was perceived to be somewhat more effective in
promoting overall well-being (mean = .34, sd = .46) than
in relieving symptoms (mean = .25, sd = .36). The most
frequently reported specific benefits were for emotional
(spiritual) well-being (50%), physical well-being (50%),
energy level (44%), and strength (41%), with far fewer
reporting benefit for specific muscle weakness. Large
minorities (30% or more) felt it helped with anxiety or
sadness, depression, daily activities and socializing with
others. While Sen-Sei-Ro was less frequently seen as effec-
tive in alleviating common symptoms that are side effects
of conventional treatment, a third or more reported bene-
Table 4: Summary Scales of Noticed Effects of Using Sen-Sei-Ro 
From 782 Respondents
Treatment 
Symptoms
Functional 
Well-being
Item-Scale Correlations1
Appetite 0.50 0.44
Maintained or gained weight 0.53 0.37
Lost weight 0.48 0.39
Feelings of pain 0.54 0.36
Ability to reduce hair loss or grow hair 0.36 0.28
Nausea or vomiting 0.44 0.38
Muscle weakness 0.39 0.51
Energy level 0.43 0.75
Physical strength 0.44 0.73
Feelings of tension, worry 0.38 0.72
Feelings of sadness, depression 0.43 0.65
Ability to spend time with other people 0.41 0.70
Ability to work or get chores done 
around the house
0.46 0.75
Overall sense of physical well being 0.50 0.75
Overall sense of emotional well being 0.39 0.70
Cronbach alpha 0.74 0.91
1 Item-scale correlations, shown in bold face, are corrected of overlap.
Items included in factor analysis, but deleted from summary scales 
because of poor scale discrimination include: falling asleep quickly; 
feeling sleepy during the day;
Table 3: Perceived Help from Sen-Sei-Ro by 782 Survey 
Respondents
Percent
How much do you think that drinking 
"Sen-Sei-Ro" helps with the following?
No 
help
Help Great 
help
A. Improves my body strength to fight 
cancer
57 02 5
B. Improves my resistance against sickness 
other than cancer
10 74 16
C. Helps reduce symptoms of cancer 10 65 24
D. Helps reduce the side effects of cancer 
therapy
12 67 21
E. Helps with cancer treatment 10 67 24
F. Helps with improving emotional condition 9 66 25
G. Helps me spiritually to fight against 
cancer
66 23 1
Table 2: History of Use of Sen-Sei-Ro Reported by 782 Survey Respondents
Characteristic Number Percent
How long have you been taking "Sen-Sei-Ro? (median: more than a year)
Less than a month 9 1.2
1–3 months 57 7.3
3–6 months 108 13.9
6 months- 1 year 172 22.1
More than 1 year 432 55.5
When did you start drinking "Sen-Sei-Ro?" (median: after starting treatment)
Before the cancer diagnosis 22 2.9
At the time of cancer diagnosis (before surgery or chemotherapy) 218 28.4
After starting the treatment (surgery or chemotherapy) 266 34
After completion of treatment (surgery or chemotherapy) 262 34.1
What best describes your situation? (median: every day)
Drink it every day (routinely) 644 84.4
Drink while I am undergoing cancer treatment 71 9.3
Drink when I am feeling poorly, tired, and weak) 22 2.9
Drink when I am feeling worried about my cancer) 26 3.4
How many packs do you drink, on the average, per week? (median: 1 pack/day)
Less than 7 packs (less than 1/day) 49 6.4
7 packs (1 pack/day) 369 48.4
2 packs/day 195 25.6
3 packs/day 126 16.5
4 or more packs/day 24 3.1BMC Complementary and Alternative Medicine 2007, 7:32 http://www.biomedcentral.com/1472-6882/7/32
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fits with respect to appetite and maintenance of body
weight. More than 1 in 5 felt it helped with sleeplessness,
pain and hair loss.
Perceived effects of using it were associated with gender,
age, and tumor site. Women and those with uterine can-
cers reported better Functional Well-Being, but parallel
trends for Relief of Symptoms did not achieve statistical
significance (Table 5). Younger patients tended to report
more positive effects on Functional Well-Being, but not
on Relief of Symptoms. Surprisingly, current active anti-
cancer treatment did not affect either scale, although
patients who began using the product earlier in their
course tended to report more benefit on Relief of Symp-
toms. The amount consumed each week was not associ-
ated with perceived effects in either domain (data not
shown).
Study participants with aggressively treated, poor progno-
sis cancers (lung, gastric and liver) tended to report less
Table 5: Perceived Effects Scale Scores by Characteristics of 782 Respondents
Relief of Treatment 
Symptoms
test of association 
(p value)
Improve Functional 
Well-being
test of association 
(p value)
(mean scores)
All Respondents 0.25 0.30
Percent reporting no net effect 26% 37%
Sex
Male 0.23 t 0.25 t
Female 0.27 (0.092) 0.36 (< 0.001)
Age group
20 – 49 0.30 0.42
50 – 59 0.27 r = -0.03 0.29 r = -0.08
60 – 69 0.23 (0.389) 0.30 (0.016)
70 and older 0.25 0.26
Cancer group
Lung, stomach, liver 0.23 F 0.28 F
Colon, breast, uterus, cervix 0.29 (0.060) 0.35 (0.004)
Prostate, other 0.21 0.15
Lung No 0.27 t 0.32 t
Yes 0.20 (0.032) 0.26 (0.190)
Stomach No 0.25 t 0.29 t
Yes 0.27 (0.379) 0.34 (0.245)
Liver No 0.26 t 0.31 t
Yes 0.18 (0.026) 0.23 (0.059)
Colon No 0.24 t 0.29 t
Yes 0.29 (0.074) 0.33 (0.295)
Breast No 0.25 t 0.29 t
Yes 0.26 (0.725) 0.36 (0.192)
Uterus No 0.25 t 0.29 t
Yes 0.39 (0.075) 0.50 (0.051)
Cervix No 0.25 t 0.30 t
Yes 0.26 (0.836) 0.42 (0.159)
Prostate No 0.25 t 0.32 t
Yes 0.21 (0.277) 0.14 (0.002)
History using sen-sei-ro
≤ 3 months 0.14* 0.22
3 – 6 months 0.24 r(s) = 0.07 0.30 r(s) = 0.04
6 – 12 months 0.25 (0.059) 0.29 (0.251)
> 12 months 0.27 0.32
Current treatment
No active treatment 0.24 F 0.31 F
Oral or radiation therapy 0.26 0.640 0.30 0.973
Intravenous chemotherapy 0.26 0.30
t: t-test.
F: F, analysis of variance.
r: Pearson correlation coefficient; r(s): Spearman correlation coefficient.
* Group mean is significantly (p < 0.05) lower than means for other groups, which are not significantly different from one anotherBMC Complementary and Alternative Medicine 2007, 7:32 http://www.biomedcentral.com/1472-6882/7/32
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benefit than those with less aggressively treated cancers
(colon, breast, uterus or cervix). Those with prostate can-
cer and other cancers that seldom received chemotherapy
during the survey period reported the least benefit.
Discussion
This survey of consumers of Sen-Sei-Ro who reported a
history of cancer found that nearly all began using it after
their cancer was diagnosed, and those who started using it
earlier in their cancer course tended to report greater ben-
efit. Most patients report benefit from consuming this
product and large proportions feel using it is a "great
help." A survey of people currently using the product by
choice produces a bias toward reported benefit, which our
results reflect, and the relatively low 33% survey response
rate probably increases the bias. However, despite the evi-
dent predisposition in favor of the product and the gener-
ally positive reports for more global benefits from its use,
most of these study participants report little substantial
effect in either direction when queried about specific con-
sequences of cancer or its treatment.
Our findings shed some light on these patients and our
measures. Our factor analysis of items focusing on 17
more or less specific effects indicated two major constructs
that characterize study participants' perceptions of poten-
tial benefits of using Sen-Sei-Ro: relief of cancer and treat-
ment-related symptoms and improvement in overall
functional status and well-being, which fits with previous
studies of cancer patients' motivations for pursuing CAM
[4,22,23]. Like others, we found that improvements in
functional well-being were greater than relief of symp-
toms, suggesting that cancer patients use CAM products
for their effects, rather like a health promoting tonic, in
strengthening their body's ability to recover from the
debility of cancer treatment and support its ability to fight
against cancer [22,24,25]. Our results provide some addi-
tional evidence of the validity of these measures. Younger
patients, women, study participants with longer usage and
thus more time to recover from initial cancer treatments,
and those whose cancers had less poor prognoses and less
aggressive treatment are all generally less symptomatic
and in better overall health, and all tended to report more
benefit by both measures. These results are consistent
with both patients' limited understanding of pathophysi-
ology and the sensitivity of these scales to their true con-
dition: they felt better and thus able to ascribe benefit to
Sen-Sei-Ro than others expected to be worse off. The still
lower benefit reported by prostate cancer patients may
reflect their better overall well-being and few symptoms
from disease or treatment, providing little potential for
benefit from Sen-Sei-Ro. The 2 scales postulated here
appear sensitive to patient changes in two domains rele-
vant to CAM use and may prove useful as outcome meas-
ures in future controlled trials of these substances in
cancer patients.
Previous studies have helped to characterize who is likely
to use dietary supplements, such as Sen-Sei-Ro and com-
plementary and alternative medicine products more
broadly. In studies of cancer patients and other popula-
tions in North America and Europe, the probability of
choosing these approaches is greater with female gender,
older age, higher education, lower body mass and indica-
tors of healthy lifestyles, such as frequent exercise, avoid-
ance of smoking, and diets low in fat and high in fruits
and vegetables [26-32]. In a large national study in Japan,
Ishihara et al. reported that 11% of men and 16% of
women used dietary supplements, with use associated
with older age, lower body mass, and frequent exercise, as
well as longer work days (for men), and greater stress [32].
The reasons cancer patients give for using dietary supple-
ments appear to revolve around three main themes, char-
acterized in one study as surviving cancer (i.e.,
augmenting conventional treatment in fighting cancer),
relieving both cancer symptoms and treatment side-
effects, and repairing or boosting up, which includes
detoxifying the body, boosting immunity and energy, and
enhancing quality of life [22].
Other surveys of cancer patients have highlighted the goal
of health restoration and promotion. The most common
reasons for using CAM cited by breast cancer patients in
Ontario were to boost the immune system (63%),
increase quality of life (53%), and prevent cancer recur-
rence (43.5%) [4]. Large numbers of both women (73%)
and men (56%) in the SEER cohort in western Washing-
ton used dietary supplements, primarily to improve gen-
eral health and well being (95% of supplement users)
[23]. However, relatively few cite symptom treatment as
reason for using CAM: 21% mentioned treating side
effects of conventional cancer treatments in the Ontario
survey, and only 4% of the VA patients gave this reason.
[4] A survey of cancer patients in the VA found that of the
61% who took a dietary supplement, 41% cited "energy
increase" as their reason [24]. When asked about benefits,
40% said it improved overall health, 21% reported
increased energy, and only 9% said dietary supplements
improved symptoms. Yet, an MD Anderson survey found
that having received chemotherapy doubled the likeli-
hood of its use and was the most common characteristic
of users [25]. Hedderson et al. found that cancer patients'
decisions to use dietary supplements are associated with
more severe treatment side effects and also a stronger
desire for personal control [29].
The distinction between symptom relief and more global
benefits echoes the distinction between the medical
model of combating specific diseases and a more broadlyBMC Complementary and Alternative Medicine 2007, 7:32 http://www.biomedcentral.com/1472-6882/7/32
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understood relationship between diet and health. The
concepts occasionally overlap, as in the well-established
diet-heart theory linking dietary components, especially
fats, to cardiac risk. However, the parallel diet-cancer the-
ory has far less epidemiological support, and the concept
of epidemic obesity in the US has apparently been
embraced slowly and fitfully despite the striking data sup-
porting it. The associations between CAM use and the
healthy lifestyle and favorable socioeconomic variables,
including higher educational and income levels, suggest
that the broader concept of diet as a tonic, not a medicine,
prevails in populations removed from severe economic
adversity. As a result, the effects patients expect and per-
ceive from Sen-Sei-Ro may have little to do with medical
specifics such as the particular cancer diagnosis, the inten-
sity of treatment and how recently it was given.
This distinction is useful for evaluating a substance taken
both to obtain a global benefit, as well as to counter an
array of specific symptoms. For example, antiemetic treat-
ment against chemotherapy-induced nausea and vomit-
ing produces quality of life benefits by reducing a specific
noxious symptom complex that are much greater than the
more global impact of erythropoietin on patients receiv-
ing chemotherapy. The two constructs we found corre-
spond to patient goals for CAM identified in other studies.
In another breast cancer patient cohort, CAM use was a
marker of psychosocial distress, which may in part have
motivated its use [33], since CAM is used more often by
more seriously ill patients.
These results imply that patient-based measures of the
effects CAM products must be strongly informed by
patients' explanatory models of cancer "pharmacology,"
which may differ from their physicians', and measure the
outcomes they value, according to their perspectives.
Measures should focus on tonic effects on body strength
and overall function as well as on symptom alleviation. If
dietary supplements are not taken primarily for symptom
relief, patients may not experience and report it, even if
that is the reason their doctors prescribed the supplement.
The stronger body patients hoped for may resist symp-
toms better, but the patient may consider that a lucky
byproduct, not the main objective.
If the benefits of Sen-Sei-Ro and related products are likely
to be global, rather than symptom-specific, investigations
should target broad measures of well-being and systemic
symptoms of anxiety or sadness, depression, appetite,
maintaining body weight, daily activities, and socializing
with others, in additional specific symptoms such as hair
loss, nausea and pain. Our use of a 3-item Likert response
set may be improved by using a 5-item scale, which would
produce less granular data with better better statistical
properties for psychometric analyses. We look forward to
further development of this instrument to assess the use of
this and other CAM substances in cancer patients. We plan
to use these results to inform a series of focus groups to
refine and supplement these items, pilot test additional
items, subject the revised instrument to further validation
studies and to use the final validated instrument in rand-
omized trials of the efficacy of Sen-Sei-Ro and other CAM
substances with putative health properties in cancer
patients, if adequate research funding is available.
Conclusion
Respondents to our survey of Sen-Sei-Ro consumers with
cancer reported favorable perceived effects from its use.
Our instrument, when further validated, may be a useful
outcome in trials assessing this and other CAM substances
in cancer patients.
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